Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma

The recent development of chemotherapeutic proteasome inhibitors, such as bortezomib, has improved the outcomes of patients suffering from the plasma cell malignancy multiple myeloma. Unfortunately, many patients treated with these drugs still suffer relapsing disease due to treatment-induced upregu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlap, Katherine M, Bartee, Mee Y, Bartee, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918372/
https://www.ncbi.nlm.nih.gov/pubmed/27512665
http://dx.doi.org/10.2147/OV.S72372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918372/
https://www.ncbi.nlm.nih.gov/pubmed/27512665
http://dx.doi.org/10.2147/OV.S72372

Ejemplares similares